The quality, and therefore the reliability, of outcome measures of the severity and/or progression of myasthenia gravis (MG) sometimes it comes up a little short, particularly in the field of clinical trials. This is the observation made by a number of experts at a meeting held in the United States with a view to making proposals for improvement:
- some scales and assessment tools, such as the MG-ADL (activities of daily living), MG-QOL-15r (quality of life) and MG-Impairment Index (measurement of impairments), have received only minor comments, with only proposals for partial rewriting of the instructions for administering them,
- others, such as the Quantitative-MG Score (QMS), have been more radically revised, leading not only to the adaptation of the test-taking manual but also to a revision of the composition of the score itself.
It is planned to disseminate these proposals for improvement very widely within the North American MG community.
